Раздел 3.1

  1. Van Rijswijk C.S., Geirnaerdt M.J., Hogendoorn P.C. et al (2004) Soft-tissue tumors: value of static and dynamic gadopentetatedimeglumine-enhanced MRI in prediction of malignancy. Radiology 233:493–502.
  2. De Schepper A.M., Bloem J.L. Soft Tissue Tumors Grading, Staging, and Tissue-Specific Diagnosis. Top Magn Reson Imaging 2007;18:431-444.
  3. De Schepper A.M., Vanhoenacker F., Gielen J., et al, eds. Imaging of Soft Tissue Tumors. 3rd ed. Berlin, Germany: Springer Verlag; 2005.
  4. Kransdorf M.J., Murphey M.D. Radiologic Evaluation of Soft-Tissue Masses: A Current Perspective. AJR 2000;175:575–587.
  5. van Rijswijk C.S., Kunz P., Hogendoorn P.C., Taminiau A.H., Doornbos J.., Bloem J.L. Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging 2002;15(3):302–307.
  6. Gielen J.L., De Schepper A.M.,Vanhoenacker F., Parizel P.M., Wang X.L., Sciot R., Weyler J (2004) Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A rospective study in 548 patients. Eur Radiol 14(12):2320–2330
  7. Igrec J., Fuchsjäger M.H. Imaging of Bone and Soft-Tissue Sarcomas. Fortschr Röntgenstr 2021; 193: 1171–1182
  8. Noebauer-Huhmann et al. Soft Tissue Tumors in Adults: ESSR Guidelines. Seminars in Musculoskeletal Radiology Vol.2015; 19. No. 5: 475-482
  9. Enzinger F.M., Weiss S.W. General considerations. In: Enzinger F.M., Weiss S.W., eds. Soft tissue tumors, 3rd ed. St. Louis: Mosby–Year Book, 1995:1–16
  10. Kransdorf M. Malignant soft tissue tumors in a large referral population: distribution of specific diagnoses by age, sex and location. AJR Am J Roentgenol. 1995;164:129Y134.
  11. Kransdorf M. Benign soft tissue tumors in a large referral population: distribution of specific diagnoses by age, sex and location. AJR Am J Roentgenol. 1995;164:395Y402.
  12. Soft Tissue and Bone Tumours. Ed. by WHO Classification of Tumours Editorial Boards. 5th Edition, Lion: IARC, 2020.
  13. American College of Radiology ACR Appropriateness Criteria: Soft Tissue Masses. https://acsearch.acr.org/docs/69434/Narrative/
  14. Rowbotham E., Bhuva S., Gupta H., Robinson P. Assessment of referrals into the soft tissue sarcoma service: evaluation of imaging early in the pathway process. Sarcoma 2012;2012
  15. Klauser A.S., Tagliafico A., Allen G.M., et al. Clinical indications for musculoskeletal ultrasound: a Delphi-based consensus paper of the European Society of Musculoskeletal Radiology. Eur Radiol 2012;22(5):1140–1148
  16. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009. Vol.45. P.228–247.
  17. Hung E.H., Griffith J.F., Ng A.W., Lee R.K., Lau D.T., Leung J.C. Ultrasound of musculoskeletal soft-tissue tumors superficial to the investing fascia. AJR Am J Roentgenol 2014;202(6): W532–W540.
  18. Kransdorf M.J., Murphey M.D. Imaging of Soft-Tissue Musculoskeletal Masses: Fundamental Concepts. Radiographics 2016;36:1931-48.
  19. Carra B.J., Bui-Mansfield L.T., O’Brien S.D., Chen D.C. Sonography of musculoskeletal soft-tissue masses: techniques, pearls, and pitfalls. AJR Am J Roentgenol 2014;202(6):1281–1290.
  20. Casali P.G., Bielack S., Abecassis N., et al; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310. PMID: 30285218.
  21. Panicek D.M., Gatsonis C., Rosenthal D.I., et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology 1997;202:237-46.
  22. Expert Panel on Musculoskeletal Imaging, Bestic J.M., Wessell D.E., Beaman F.D., Cassidy R.C., Czuczman G.J., Demertzis J.L., Lenchik L., Motamedi K., Pierce J.L., Sharma A., Sloan A.E., Than K.., Walker E.A., Ying-Kou Yung E., Kransdorf M.J. ACR Appropriateness Criteria® Primary Bone Tumors. J Am Coll Radiol. 2020 May;17(5S):S226-S238. doi: 10.1016/j.jacr.2020.01.038. PMID: 32370967.
  23. Pettersson H., Gillespy T., Hamlin D.J., et al. Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities. Radiology 1987;164:237–241.
  24. Bloem J.L., Taminiau A.H.M., Eulderink F., Hermans J., Pauwels E.K. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. Radiology 1988;169:805–810
  25. Manaster B.J. Soft-tissue masses: optimal imaging protocol and reporting. AJR Am J Roentgenol 2013;201(3):505–514
  26. Замогильная Янна Александровна. Современные методы лучевой диагностики в оценке эффекта предоперационной химиотерапии у больных с саркомами мягких тканей конечностей диссертация на соискание ученой степени кандидата медицинских наук, Москва, 2014.
  27. Замогильная Я.А., Блудов А.Б., Кочергина Н.В., Бохян Б.Ю., Близнюков О.П., Неред А.С. Роль МРТ в оценке эффекта лечения опухолей мягких тканей // Бюллетень сибирской медицины. 2012. Т. 11. № S1. С. 50–52.
  28. Замогильная Я.А., Алиев М.Д. Оценка эффективности предоперационной терапии с помощью лучевой диагностики у больных саркомами мягких тканей // Саркомы костей, мягких тканей и опухоли кожи. 2013. № 2. С. 3–10.
  29. Блудов А.Б., Замогильная Я.А., Неред А.С., Кочергина Н.В., Бохян Б.Ю., Мачак Г.Н., Феденко А.А., Анурова О.А., Заспа О.А. Основы методики контрастной МРТ в оценке эффективности предоперационной химиотерапии у больных с саркомами костей и мягких тканей // Саркомы костей, мягких тканей и опухоли кожи. 2011. № 4. С. 41–50.
  30. Крылов А.С., Рыжков А.Д., Щипахина Я.А., Гончаров М.О. Перфузионная сцинтиграфия с 99mТс-технетрилом и магнитно-резонансная томография с динамическим контрастированием в диагностике сарком мягких тканей // Медицинская радиология и радиационная безопасность. 2016. Т. 61. № 5. С. 48–53.
  31. Щипахина Я.А., Блудов А.Б., Неред А.С., Кочергина Н.В., Ануров О.А., Ротобельская Л.Е. Магнитно-резонансная томография в оценке эффекта предоперационной химиотерапии у больных с саркомами мягких тканей опорно-двигательного аппарата // Диагностическая и интервенционная радиология. 2017. Т. 11. № 1. С. 18–27.
  32. El Kady R.M., Choudhary A.K., Tappouni R. Accuracy of apparent diffusion coefficient value measurement on PACS workstation: a comparative analysis. AJR Am J Roentgenol 2011;196(3):W280–W284.
  33. Einarsdóttir H., Karlsson M., Wejde J., Bauer H.C. Diffusion-weighted MRI of soft tissue tumours. Eur Radiol 2004;14 (6):959–963.
  34. Subhawong T.K., Jacobs M.A., Fayad L.M. Diffusion-weighted MR imaging for characterizing musculoskeletal lesions. RadioGraphics 2014;34(5):1163–1177.
  35. Oliveira A.M., Nascimento A.G. Grading in soft tissue tumors: principles and problems. Skeletal Radiol. 2001;30: 543Y559.
  36. Peabody T.D., Simon M.A. Principles of staging of soft-tissue sarcomas. Clin Orthop 1993;289:19–31.
  37. Verstraete K.L., De Deene Y., Roels H., et al. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MRI – parametric “firstpass” images depict tissue vascularization and perfusion. Radiology. 1994. Vol. 192. P:835–43.
  38. Baert A.L., Sartor K. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Springer. 2005, ch. 6, p. 81-92.
  39. Verstraete K.L., Vanzieleghem B., De Deene Y., et al. Static, dynamic and first-pass MRI of musculoskeletal lesions using gadodiamide injection. Acta Radiol. 1995. Vol. 36. № 1. Р:27–36.
  40. Kransdorf M., Jelinek J., Moser R. (1993) Imaging of soft tissue tumors. Radiol Clin North Am 31:359–372
  41. Lisson C.S. et al. Radiological Diagnosis of Soft Tissue Tumors in Adults: MRI Imaging of Selected Entities Delineating Benign and Malignant Tumors. Fortschr Röntgenstr 2019; 191: 323–332.
  42. Stramare R., Beltrame V., Gazzola M. et al. Imaging of soft-tissue tumors.J Magne Reson Imaging 2013;37:791-804.
  43. Murphey M.D., Smith W.S., Smith S.E. et al. From the archives of the AFIP. Imaging of musculoskeletal neurogenic tumors: radiologic-pathologic correlation. Radiographics 1999; 19: 1253–1280.
  44. Coyle J., White L.M.., Dickson B, et al. MRI characteristics of nodular fasciitis of the musculoskeletal system. Skeletal Radiol 2013;42:975–82.
  45. Bancroft L., Kransdorf M., Menke D., O'Connor M., Foster W. Intramuscular Myxoma: Characteristic MR Imaging Features. AJR Am J Roentgenol. 2002;178(5):1255-9.
  46. T. Nakamura, T .Hagi, K. Asanuma, A. Sudo Intra-articular synovial sarcoma in the ankle joint: a case report Mol Clin Oncol, 9 (4) (2018), pp. 464-466.
  47. Vadapalli R., G. Hegde, R. Botchu et al. MRI imaging of soft tissues tumours and tumour like lesions-SLAM approach. J Clin Orthop Trauma 2022;16:28:101872.
  48. Kransdorf M.J., Bancroft L.W., Peterson J.J. et al. Imaging of fatty tumors: distinction of lipoma and well-differentiated liposarcoma. Radiology 2002; 224: 99–104.
  49. Peterson J.J., Kransdorf M.J., Bancroft L.W. et al. Malignant fatty tumors: classification, clinical course, imaging appearance and treatment. Skeletal Radiol 2003; 32: 493-503.
  50. D. Malik, V. Pant, I. Sen, et al. The role of PET-CT-guided metabolic biopsies in improving yield of inconclusive anatomical biopsies: A review of 5 years in a teaching hospital Diagnostics (Basel), 13 (13) (2023), pp. 1-9
  51. Benz M.R., Dry S.M., Eilber F.C., et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med 2010;51:1174-81.
  52. Kubo T., Furuta T., Johan M.P., Ochi M. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis. Eur J Cancer 2016;58:104-11
  53. Roberge D., Vakilian S., Alabed Y.Z., et al. FDG PET/CT in initial staging of
adult soft-tissue sarcoma. Sarcoma 2012;2012:960194, https://doi.org/ 10.1155/2012/960194.
  1. Sambri A., Bianchi G., Longhi A., et al. The role of 18F-FDG PET/CT in soft tissue sarcoma. Nucl Med Commun 2019;40:626e31. https://doi.org/ 10.1097/MNM.0000000000001002.
  2. American Joint Committee on Cancer. Soft Tissue Sarcoma Stages. https://www.cancer.org/cancer/soft-tissue-sarcoma/detection-diagnosis-staging/staging.html Последнее обновление 6 апреля, 2018 г.
  3.  Lucas J.D., O’Dohetry M.J., Wong J.C., et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft tissue sarcomas. J Bone Joint Surg Br. 1998;80:441–447.
  4. Hagi T., Nakamura T., Sugino Y., Matsubara T., Asanuma K., Sudo A. Is FDG-PET/CT useful for diagnosing pulmonary metastasis in patients with soft tissue sarcoma? Anticancer Res. 2018;38:3635–3639.
  5. Macpherson R.E., Pratap S., Tyrrell H., et al. Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma. Clin Sarcoma Res. 2018;8:9.
  6. Tateishi U., Yamaguchi U., Seki K., Terauchi T., Arai Y., Kim E.E. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology. 2007;245:839–847.
  7. Vincenzi B., Frezza A.M., Schiavon G., et al. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res 2013;3(1):6.
  8. Bosma S.E., Vriens D., Gelderblom H., van de Sande M.A.J., Dijkstra P.D.S.,Bloem J.L. (2019) (18)F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. Skeletal Radiol 48:1735–1746/
  9. Yang H.L., Liu T., Wang X.M., Xu Y., Deng S.M. (2011) Diagnosis of bonemetastases: a meta-analysis comparing (1)(8)FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617.
  10. Sarcoma NCPGiOST (2023) Network version 2.2023. J Natl Compr Canc Netw
  11. Volker T., Denecke T., Steffen I. et al (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25:5435–5441.
  12. Sambri A., Bianchi G., Longhi A. et al (2019) The role of 18F-FDG PET/CT in soft tissue sarcoma. Nucl Med Commun 40:626–631
  13. Espat N.J., Bilsky M., Lewis J.J., Leung D., Brennan M.F. Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients. Cancer 2002;94(10):2706–2711
  14. Haniball J., Sumathi V.P., Kindblom L.G., et al. Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma. Sarcoma 2011;2011:538085
  15. Roberge D., Vakilian S., Alabed Y.Z., Turcotte R.E., Freeman C.R., Hickeson M. FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma 2012;2012:960194
  16. Клинические рекомендации, одобренные научным советом МЗ РФ, Саркомы мягких тканей, 2020 г.
  17. Vanel D., Lacombe M.J., Couanet D., et al. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology. 1987. Vol. 164. №1. Р:243–245.
  18. Siegel M.J. Magnetic resonance imaging of musculoskeletal soft tissue masses. RadiolClin North Am. 2001. Vol. 39. №4. P:701–720.
  19. Roberge D., Skamene T., Nahal A., et al. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol. 2010. Vol.97. №3. Р: 404-407.
  20. Erlemann R., Sciuk J., Bosse A., et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990; Vol. 175. P:791–796.
  21. Einarsdottir H., Wejde J., Bauer H. Pre-operative radiotherapy in soft tissue tumors. Assessment of response by static post-contrast MRI compared with histopathology. Acta Radiologica. 2001. Vol. 42. №1. Р:1–4.
  22. VanRijswijk C.S., Geirnaerdt M.J., Hogendoorn P.C. et al. Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol. 2003. Vol. 13. № 8. Р: 1849-1858.
  23. Einarsdottir H., Karlsson M., Wejde J., Bauer H.C. Diffusion-weighted MRI of soft tissue tumors. Eur Radiol. 2004. Vol. 14. № 6. Р:336-343.
  24. A. Gronchi, A.B. Miah, A.P. Dei Tos, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2021, Vol. 32, Issue 11, 1348-1365
  25. Eary J.F., O'Sullivan F., Powitan Y., et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-1154.
  26. Schuetze S.M., Rubin B.P., Vernon C., et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-348.
Benz M.R., Czernin J., Allen-Auerbach M.S., et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856-2863.